According to EqualOcean, the biotechnology and life science intelligent automation company HCSCI（瀚辰光翼）recently successfully completed a B+ round financing of over CNY 300 million, bringing its total funding in the B series to over CNY 500 million.
This round of financing was jointly led by Lake Bleu Capital（清池资本） and Guotai Junan Innovation Investment（国泰君安创新投资）, with participation from Dalton Venture（道彤投资）, and Eightfold Venture Partners (循正创投). Existing shareholders Legend Capital（君联资本） and LYFE Capital（洲嶺资本） also made additional investments, while Hyperspace Capital（多维资本） served as the exclusive financial advisor for this round of financing.
Established in 2016 and headquartered in the BIO-town（成都天府国际生物城） in Chengdu, HCSCI's mission is to "empower life sciences, achieve the extraordinary without complexity." The company specializes in the life science field, focusing on developing innovative high-throughput automated molecular detection equipment. HCSCI serves global life science clients and promotes the application and development of molecular detection technology in areas such as medical testing, modern agriculture, health management, and pharmaceutical research.
Since its inception, HCSCI has been dedicated to the research and development of biotechnology equipment. The company has successfully broken the monopoly of imported equipment and introduced a comprehensive range of equipment and solutions with full-stack proprietary intellectual property rights based on mainstream molecular detection technologies like PCR and sequencing. This includes industry-leading high-throughput genetic typing systems, fully automated multifunctional gene detection systems, and automated nucleic acid concentration detection and homogenization workstations. Moreover, HCSCI has successfully delivered multiple unmanned intelligent laboratory production lines.
These products and solutions above find extensive application in various major crops as well as high-end vegetables, fruits, and livestock and poultry breeding in modern agriculture. They are used for variety identification, germplasm resource protection and exploration, molecular marker-assisted breeding, whole-genome selection breeding, and other applications.
According to statistics and forecasts by QYResearch（恒州博智）the sales revenue of China's life science automation system market reached USD 1.087 billion in 2022 and is expected to reach USD 1.506 billion by 2029, with a compound annual growth rate of 4.71%. In this market, HCSCI will continue to play a significant role.
The funds raised in this round will primarily support HCSCI's new product development, market expansion, overseas business development, and team building in the field of biotechnology and life science. This will further strengthen HCSCI's product and market presence in relevant fields, enhance its brand influence, and contribute to advancing intelligent automation in biotechnology and life science.